RFI: CBRN Advance Defense Enabling Network and Clinical Capability (CADENCC) program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Army, specifically the CPE-CBRND-ET within the Department of War, has issued a Request for Information (RFI) for the CBRN Advance Defense Enabling Network and Clinical Capability (CADENCC) program. This RFI seeks to identify an "Integrator" and gather information on capabilities to strengthen a clinical site network for the rapid development, testing, and evaluation of Medical Countermeasures (MCMs) against CBRN threats. Responses are due March 25, 2026.
Purpose and Scope
The CADENCC program is a Medical Architecture Accelerator designed to streamline advanced development activities for MCMs. The goal is to establish a robust clinical site network capable of generating safety and efficacy data, potentially utilizing disease-agnostic Master Protocols. The network should handle studies with healthy volunteers and patient populations under rapid response timelines. This RFI is for planning purposes only and does not constitute a solicitation.
Key Information Requested
Respondents should demonstrate capabilities and experience in the following areas:
- Clinical Site Network Expansion: Managing multi-site clinical trial networks (CONUS/OCONUS), performing concurrent trials, and coordinating diverse site groups (federal, state, public health, military, academic, private).
- Accelerated Clinical Trial Initiation: Experience with Phase 1 & 2 trials, innovative strategies for rapid study start-up/execution/close-out, development of master protocols, and effective subject identification/enrollment.
- Decentralized Data Collection: Leveraging digital health technologies, AI, and remote approaches for data collection, safety monitoring, and participant recruitment.
- Accelerated MCM Evaluation: Ability to conduct clinical trials across various product modalities (biologics, small molecules, vaccines, devices) and administration routes, while maintaining regulatory rigor.
- Quality Assurance Capabilities: Adherence to GCP, Risk-Based Monitoring (RBM), robust SOPs, data management integrity, Quality Management Systems (QMS) (e.g., ISO 9001:2015, MIL-STD-1916 alignment), and auditing/inspection practices.
- Configuration Management Capabilities: Experience in requirements, data, change, records, and library management, as well as document control.
- Program Management Capabilities: Technical/administrative support, SOPs, supply chain management, and risk management.
Submission Details
- Response Due: March 25, 2026, by 21:00:00Z
- Page Limit: 10 pages
- Submission Method: Email to David Bailey (david.e.bailey113.civ@army.mil) with a courtesy copy to Hunter T Robinson (hunter.t.robinson4.civ@army.mil).
- Set-Aside: Not applicable (RFI for information gathering).
- Place of Performance: Frederick, MD, United States.